Skip to main content
SpringerLink
Log in

Principles of Medical Management of Ulcerative Colitis

  • Chapter
  • First Online:
Medical Therapy of Ulcerative Colitis

  • 1303 Accesses

Abstract

Ulcerative colitis (UC) is a chronic inflammatory disease with a relapsing-remitting course. It affects patients in young adulthood, with a mean age of 34.5 years at diagnosis, a point in life when the afflicted individuals are completing their higher education, establishing their careers, and starting their families. As patients with UC have a normal lifespan, the relapsing course of the disease portends decades of morbidity. The choice of therapy must take into account the long-term issues of compliance and adverse events. In addition, UC is a pervasive disease that can impinge on every aspect of a person’s life, from their current functional and mental state to their future reproductive health and risk of malignancy. Optimal management of this chronic condition must therefore be comprehensive in addressing every facet of the disease. This chapter discusses the principles of management of UC patients, with a focus on evidence-based, patient-centered, systematic, and comprehensive therapy. We provide an overview of the therapeutic options and goals of treatment and provide recommendations for individualizing treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut. 2000;46:336–43.

    PubMed Central  PubMed  Google Scholar 

  2. Hoie O, Schouten LJ, Wolters FL, et al. Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis. Gut. 2007;56:497–503.

    CAS  PubMed Central  PubMed  Google Scholar 

  3. Bodenheimer T, Wagner EH, Grumbach IK. Improving primary care for patients with chronic illness. JAMA. 2002;288:1775–9.

    PubMed  Google Scholar 

  4. Bodenheimer T, Wagner EH, Grumbach IK. Improving primary care for patients with chronic illness: the chronic care model, part 2. JAMA. 2002;288:1909–14.

    PubMed  Google Scholar 

  5. Nguyen GC. Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1233–9.

    PubMed Central  PubMed  Google Scholar 

  6. Bernstein KI, et al. Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:590–8.

    PubMed  Google Scholar 

  7. Robinson A. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet. 2001;358:976–81.

    CAS  PubMed  Google Scholar 

  8. Elkjaer M. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided “Constant-care” approach. Gut. 2010;59(12):1652–61.

    PubMed  Google Scholar 

  9. Wagner EH, Austin BT, Davis C, et al. Improving chronic illness care: translating evidence into action. Health Aff. 2001;20:64–78.

    CAS  Google Scholar 

  10. Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23.

    PubMed  Google Scholar 

  11. Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–9.

    PubMed Central  PubMed  Google Scholar 

  12. Singh H. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology. 2009;136(2):451–8.

    PubMed  Google Scholar 

  13. Herrinton LJ, Liu L, Fireman B, et al. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998–2005. Gastroenterology. 2009;137:502–11.

    PubMed  Google Scholar 

  14. Jelsness-Jørgensen LP, Bernklev T, Henriksen M, et al. Is patient reported outcome (PRO) affected by different follow-up regimens in inflammatory bowel disease (IBD)? A one year prospective, longitudinal comparison of nurse-led versus conventional follow-up. J Crohns Colitis. 2012;6(9):887–94.

    PubMed  Google Scholar 

  15. Bitton A, Sewitch MJ, Peppercorn MA, et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol. 2003;98:2203–8.

    PubMed  Google Scholar 

  16. Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med. 2004;66:79–84.

    PubMed  Google Scholar 

  17. Persoons P, Vermeire S, Demyttenaere K, et al. The impact of major depressive disorder on the short- and long-term outcome of Crohn’s disease treatment with infliximab. Aliment Pharmacol Ther. 2005;22:101–10.

    CAS  PubMed  Google Scholar 

  18. Boye B, Lundin KE, Jantschek G, et al. INSPIRE study: does stress management improve the course of inflammatory bowel disease and disease-specific quality of life in distressed patients with ulcerative colitis or Crohn’s disease? A randomized controlled trial. Inflamm Bowel Dis. 2011;17:1863–73.

    PubMed  Google Scholar 

  19. Diaz Sibaja MA, Comeche Moreno MI, Mas Hesse B. Protocolized cognitive-behavioural group therapy for inflammatory bowel disease. Rev Esp Enferm Dig. 2007;99:593–8.

    CAS  PubMed  Google Scholar 

  20. Goodhand JR, Greig FI, Koodun Y, et al. Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study. Inflamm Bowel Dis. 2012;18:1232–9.

    CAS  PubMed  Google Scholar 

  21. Kappelman MD, Palmer L, Boyle BM, et al. Quality of care in inflammatory bowel disease: a review and discussion. Inflamm Bowel Dis. 2010;16:125–33.

    PubMed  Google Scholar 

  22. Reddy SI, Friedman S, Telford JJ, et al. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol. 2005;100:1357–61.

    PubMed  Google Scholar 

  23. Mawdsley JE, Irving PM, Makins RJ, et al. Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics. Eur J Gastroenterol Hepatol. 2006;18:249–53.

    PubMed  Google Scholar 

  24. American Gastroenterological Association. Adult inflammatory bowel disease physician performance measures set. 2011; http://www.ama-assn.org/resources/doc/pcpi/inflammatory-bowel-disease.pdf.

  25. Ekbom A, Helmick C, Zack M, et al. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology. 1991;100:350–8.

    CAS  PubMed  Google Scholar 

  26. Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23.

    PubMed  Google Scholar 

  27. Hanauer SB. Inflammatory bowel disease. N Engl J Med. 1996;334:841–8.

    CAS  PubMed  Google Scholar 

  28. Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol. 2003;98:2363–71.

    PubMed  Google Scholar 

  29. D’Haens G, Sandborn WJ, Feagan B, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–86.

    PubMed  Google Scholar 

  30. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955;2:1041–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  31. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13:833–7.

    CAS  PubMed  Google Scholar 

  32. Seo M, Okada M, Yao T, et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992;87:971–6.

    CAS  PubMed  Google Scholar 

  33. Seo M, Okada M, Yao T, et al. Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between new activity index and Truelove and Witts classification. Am J Gastroenterol. 1995;90:1759–63.

    CAS  PubMed  Google Scholar 

  34. Seo M, Okada M, Yao T, et al. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol. 2002;37:29–34.

    PubMed  Google Scholar 

  35. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–11.

    PubMed  Google Scholar 

  36. Seo M, Okada M, Maeda K, et al. Correlation between endoscopic severity and clinical activity index in ulcerative colitis. Am J Gastroenterol. 1998;93:2124–9.

    CAS  PubMed  Google Scholar 

  37. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317:1625–9.

    CAS  PubMed  Google Scholar 

  38. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894–8.

    CAS  PubMed  Google Scholar 

  39. Higgins PD, Schwartz M, Mapili J, et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005;54:782–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  40. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005;201:1205–15.

    CAS  PubMed Central  PubMed  Google Scholar 

  41. Sharon P, Ligumsky M, Rachmilewitz D, et al. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978;75:638–40.

    CAS  PubMed  Google Scholar 

  42. Ahnfelt-Ronne I, Nielsen OH, Christensen A, et al. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology. 1990;98:1162–9.

    CAS  PubMed  Google Scholar 

  43. Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:601–16.

    CAS  PubMed  Google Scholar 

  44. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478–85.

    CAS  PubMed  Google Scholar 

  45. Kane S, Cohen RD, Aikens JE, et al. Predictors of non-compliance with mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929–32.

    CAS  PubMed  Google Scholar 

  46. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39–43.

    PubMed  Google Scholar 

  47. Kane S, Huo D, Kalyani M. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003;1:170–3.

    CAS  PubMed  Google Scholar 

  48. Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007;13:629–38.

    PubMed  Google Scholar 

  49. Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95:1263–76.

    CAS  PubMed  Google Scholar 

  50. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867–71.

    CAS  PubMed  Google Scholar 

  51. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalamine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomized, double blind, placebo controlled study. Gut. 2005;54:960–5.

    CAS  PubMed Central  PubMed  Google Scholar 

  52. D’Albasio G, Pacini F, Camarri E, et al. Combination therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol. 1997;92:1143–7.

    PubMed  Google Scholar 

  53. Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.

    CAS  PubMed  Google Scholar 

  54. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955;2:1041–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  55. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:590–9.

    CAS  PubMed  Google Scholar 

  56. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;1:1067–70.

    CAS  PubMed  Google Scholar 

  57. Truelove SC, Willoughby CP, Lee EG, et al. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet. 1978;2:1086–8.

    CAS  PubMed  Google Scholar 

  58. Jarnerot G, Rolyn P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology. 1985;89:1005–13.

    CAS  PubMed  Google Scholar 

  59. Abu-Suboh Abadia M, Casellas F, Vilaseca J, et al. Response of first attack of inflammatory bowel disease requiring hospital admission to steroid therapy. Rev Esp Enferm Dig. 2004;96(539–44):544–7.

    Google Scholar 

  60. Bossa F, Fiorella S, Caruso N, et al. Continuous versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol. 2007;102:601–8.

    PubMed  Google Scholar 

  61. Carbonnel F, Gargouri D, Lemann M, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther. 2000;14:273–9.

    CAS  PubMed  Google Scholar 

  62. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905–10.

    CAS  PubMed Central  PubMed  Google Scholar 

  63. Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23.

    PubMed  Google Scholar 

  64. Baron JH, Connell AM, Kanaglunis TG, et al. Outpatient treatment of ulcerative colitis: comparison between three doses of oral prednisone. Br Med J. 1962;2:441–3.

    CAS  PubMed Central  PubMed  Google Scholar 

  65. Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143:1218–26.

    CAS  PubMed  Google Scholar 

  66. Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2013. [Epub ahead of print].

    Google Scholar 

  67. Bossa F, Fiorella S, Caruso N, et al. Continuous versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol. 2007;102:601–8.

    PubMed  Google Scholar 

  68. Mulder CJ, Fockens P, Meijer DW, et al. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol. 1996;8:549–54.

    CAS  PubMed  Google Scholar 

  69. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Eng J Med. 1994;330:1841–5.

    CAS  Google Scholar 

  70. Van Assche G, Vermeire S, Rutgeerts P. Management of acute severe ulcerative colitis. Gut. 2011;60:130–3.

    PubMed  Google Scholar 

  71. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760–5.

    CAS  PubMed  Google Scholar 

  72. D’Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2011;120:1323–9.

    Google Scholar 

  73. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940–87.

    CAS  PubMed  Google Scholar 

  74. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423–33.

    CAS  PubMed  Google Scholar 

  75. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporine in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999;94:1587–92.

    CAS  PubMed  Google Scholar 

  76. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis. 2002;8:317–24.

    PubMed  Google Scholar 

  77. Hogenauer C, Wenzl HH, Hinterleitner TA, et al. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther. 2003;18:415–23.

    CAS  PubMed  Google Scholar 

  78. Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2012;18:803–8.

    PubMed  Google Scholar 

  79. Atreya I, Neurath MF. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications. Expert Rev Gastroenterol Hepatol. 2008;2:23–34.

    CAS  PubMed  Google Scholar 

  80. Chouchana L, Narjoz C, Beaune P, et al. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:15–36.

    CAS  PubMed  Google Scholar 

  81. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329–39.

    CAS  PubMed  Google Scholar 

  82. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47–53.

    CAS  PubMed Central  PubMed  Google Scholar 

  83. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol. 2004;99:1122–8.

    CAS  PubMed  Google Scholar 

  84. Sood A, Midha V, Sood N, et al. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol. 2000;19:14–6.

    CAS  PubMed  Google Scholar 

  85. George J, Present DH, Pou R, et al. The long-term outcome of ulcerative colitis treated with 5-mercaptopurine. Am J Gastroenterol. 1996;91:1711–4.

    CAS  PubMed  Google Scholar 

  86. Ardizzone S, Molteni P, Imbesi V, et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol. 1997;25:330–3.

    CAS  PubMed  Google Scholar 

  87. Chebli LA, Chaves LD, Pimentel FF, et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2010;16:613–9.

    PubMed  Google Scholar 

  88. Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:630–42.

    CAS  PubMed  Google Scholar 

  89. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641–9.

    CAS  PubMed  Google Scholar 

  90. Toruner M, Loftus Jr EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36.

    PubMed  Google Scholar 

  91. Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut. 2009;58:1427–36.

    CAS  PubMed  Google Scholar 

  92. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology. 1996;110:1416–21.

    CAS  PubMed  Google Scholar 

  93. Orth T, Peters M, Schlaak JF, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol. 2000;95:1201–7.

    CAS  PubMed  Google Scholar 

  94. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New Engl J Med. 2005;353:2462–76.

    CAS  PubMed  Google Scholar 

  95. Panccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC success trial. Gastroenterology. 2011;140:S-134.

    Google Scholar 

  96. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.

    CAS  PubMed  Google Scholar 

  97. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250–60.

    CAS  PubMed  Google Scholar 

  98. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–11.

    PubMed  Google Scholar 

  99. Gustavsson A, Jarnerot G, Hertervig E, et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis—3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther. 2010;32:984–9.

    CAS  PubMed  Google Scholar 

  100. Laharie D, Bourreille A, Branche J, et al. Cyclosporin versus infliximab in severe acute ulcerative colitis refractory to intravenous steroids: a randomized trial. Gastroenterology. 2011;140:S-112.

    Google Scholar 

  101. Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol. 2004;16:1167–71.

    PubMed  Google Scholar 

  102. Leblanc S, Allez M, Seksik P, et al. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2011;106:771–7.

    CAS  PubMed  Google Scholar 

  103. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology. 2003;124:917–24.

    CAS  PubMed  Google Scholar 

  104. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409–22.

    CAS  PubMed Central  PubMed  Google Scholar 

  105. Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009;15:1302–7.

    PubMed  Google Scholar 

  106. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther. 2008;28:966–72.

    CAS  PubMed  Google Scholar 

  107. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–7.

    CAS  PubMed  Google Scholar 

  108. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–65.

    CAS  PubMed  Google Scholar 

  109. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut. 1986;27:1210–2.

    CAS  PubMed Central  PubMed  Google Scholar 

  110. Mantzaris GJ, Hatzis A, Kontogiannis P, et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol. 1994;89:43–6.

    CAS  PubMed  Google Scholar 

  111. Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23.

    PubMed  Google Scholar 

  112. Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126:364–71.

    CAS  PubMed  Google Scholar 

  113. Pullan RD, Rhodes J, Ganesh S. Transdermal nicotine for active ulcerative colitis. New Engl J Med. 1994;330:811–5.

    CAS  PubMed  Google Scholar 

  114. Thomas GA, Rhodes J, Mani V, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med. 1995;332:988–92.

    CAS  PubMed  Google Scholar 

  115. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotics VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105:2218–27.

    PubMed Central  PubMed  Google Scholar 

  116. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1202–9.

    PubMed  Google Scholar 

  117. de Silva PS, Olsen A, Christensen J, et al. An association between dietary arachidonic acid, measured in adipose tissue, and ulcerative colitis. Gastroenterology. 2010;139:1912–7.

    PubMed  Google Scholar 

  118. Dickinson RJ, Ashton MG, Axon AT, et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology. 1980;79:1199–204.

    CAS  PubMed  Google Scholar 

  119. McIntyre PB, Powell-Tuck J, Wood SR, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut. 1986;27:481–5.

    CAS  PubMed Central  PubMed  Google Scholar 

  120. Sands BE, Ooi CJ. A survey of methodological variation in the Crohn’s disease activity index. Inflamm Bowel Dis. 2005;11:133–8.

    PubMed  Google Scholar 

  121. Irvine EJ. Quality of life issues in patients with inflammatory bowel disease. Am J Gastroenterol. 1997;92:18S–24.

    CAS  PubMed  Google Scholar 

  122. Jowett SL, Seal CJ, Barton JR, et al. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 2001;96:2921–8.

    CAS  PubMed  Google Scholar 

  123. Ott C, Liebold A, Takses A, et al. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. Gastroenterol Res Pract. 2012;2012:595970.

    PubMed Central  PubMed  Google Scholar 

  124. Goodhand JR, Kamperidis N, Rao A, et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:513–9.

    PubMed  Google Scholar 

  125. Voegtlin M, Vavricka SR, Schoepfer AM, Swiss IBD Cohort Study, et al. Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. J Crohns Colitis. 2010;4:642–8.

    PubMed  Google Scholar 

  126. Gisbert JP, Bermejo F, Pajares R, et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis. 2009;15:1485–91.

    PubMed  Google Scholar 

  127. Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123–30.

    PubMed  Google Scholar 

  128. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol. 2011;106:713–8.

    PubMed  Google Scholar 

  129. Soderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136:1561–7.

    PubMed  Google Scholar 

  130. Jess T, Simonsen J, Jørgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143:375–81.

    PubMed  Google Scholar 

  131. Meucci G, Fasoli R, Saibeni S, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis. 2012;18:1006–10.

    PubMed  Google Scholar 

  132. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–22.

    PubMed  Google Scholar 

  133. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16:338–46.

    PubMed  Google Scholar 

  134. Rutgeerts P, Vermeire S, van AG. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453–5.

    CAS  PubMed Central  PubMed  Google Scholar 

  135. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2:219–25.

    PubMed  Google Scholar 

  136. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–201.

    CAS  PubMed  Google Scholar 

  137. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991;32:174–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  138. Rubin DT, Huo D, Hetzel JT, et al. Increased degree of histological inflammation predicts colectomy and hospitalization in patients with ulcerative colitis. Gastroenterology. 2007;132:A-19. Abstract 103.

    Google Scholar 

  139. Higgins P, Schwartz M, Mapili J, Zimmermann EM. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis. Am J Gastroenterol. 2005;100:355–61.

    PubMed  Google Scholar 

  140. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–9.

    PubMed  Google Scholar 

  141. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  142. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099–105. quiz 1340–1.

    PubMed Central  PubMed  Google Scholar 

  143. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59:666–89.

    PubMed  Google Scholar 

  144. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95.

    CAS  PubMed  Google Scholar 

  145. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Barnes Jewish Hospital, Washington University, 918 Woodway Circle, St. Louis, MO, 63110, USA

    Hongha T. Vu M.D.

  2. Department of Medicine, Barnes Jewish Hospital, Washington University, 660 S. Euclid Avenue, Box 8124, St. Louis, MO, 63110, USA

    Themistocles Dassopoulos M.D.

Authors
  1. Hongha T. Vu M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Themistocles Dassopoulos M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Themistocles Dassopoulos M.D. .

Editor information

Editors and Affiliations

  1. Gastroenterology Division, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

    Gary R. Lichtenstein

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Vu, H.T., Dassopoulos, T. (2014). Principles of Medical Management of Ulcerative Colitis. In: Lichtenstein, G. (eds) Medical Therapy of Ulcerative Colitis. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1677-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1677-1_4

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1676-4

  • Online ISBN: 978-1-4939-1677-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation